Product Datasheet: GWB-36BA84 - Chlamydia pneumoniae IgA - Genway Biotech
Chlamydia pneumoniae IgA
Data Sheet
Product Number GWB-36BA84
Product Page
Name Chlamydia pneumoniae IgA
Size 96 Wells
GenWay Legacy ID(s) 40-521-475068
Related Product Names (Synonyms) Chlamydia pneumoniae IgA – ELISA
Molecular Weight 0.5
Storage The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.
Intended Use Research Use Only
Availability Available
Description Please click here for MSDS PDF Datasheet

Product Name: Chlamydia pneumoniae IgA ? ELISA

# of Samples: 1 x 96 Assays

Intended Use: The Chlamydia pneumoniae IgA-ELISA is intended for the qualitative determination of IgA class antibodies against Chla-mydia pneumoniae in human serum or plasma (citrate).

Introduction: Chlamydiae are no motile, Gram negative and obligatory intracellular growing bacteria which form characteristic inclusions within the cytoplasm of parasitized cells. They are easily visible in the light microscope. Three different Chlamydia species pathogenic for humans are known: Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci, and one species only pathogenic for animals (C. pecorum). Chlamydia trachomatis is the most prevalent agent of sexually transmitted diseases worldwide (400-500 million cases) and the number of infections is constantly growing. Pregnant women infected with C. trachomatis may transmit these bacteria during childbirth, causing conjunctivitis or pneumonia in newborns. Untreated cases of chlamydial infection can lead to chronic salpingitis, possibly resulting in ectopic pregnancy or infertility. In males, C. trachomatis is a major cause of non-gonococcal urethritis. A severe problem in Chlamydia infections is the frequent asymptomatic insidious course which may result in the initiation of chronic diseases. In many instances primary infections are not recognized and only the sequelae caused by ascended, persisting agents are diagnosed.
Infection may be identified by
Microscopy: Giemsa stain
Serology: Detection of antigens by ELISA
Detection of antibodies by IF, EIA, ELISA

Principles of the assay: The qualitative immunoenzymatic determination of IgA-class antibodies against Chlamydia pneumoniae is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique.
Microtiter strip wells are precoated with Chlamydia pneumoniae antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgA conjugate is added. This conjugate binds to the captured Chlamydia pneumoniae-specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of Chlamydia pneumoniae-specific IgA antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.

Storage and Stability: The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.

Limitations of the Test: Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data.
In immunsuppremized patients and newborns serological data only have restricted value.
The Chlamydia pneumoniae antigen which is coated on the plates is comprised of elementary bodies. A cross reaction with Chlamydia trachomatis cannot be excluded with sera containing antibodies to LPS and MOMP.

References Hoyme U.B., Spitzbart H. (1996). Past and current prevalence of Chlamydia trachomatis in women in Germany. In: Chlamydia Research. Angelika Stary (ed.). Proceedings of the third meeting of the European Society for Chlamydia Research, Vienna, Austria, 11.-14. Sept. p. 391.Paavonen J. (1996). Chlamydia trachomatis: A major cause of mucopurulent cervicitis and pelvic inflammatory disease in women. In: Sexually Transmitted Diseases. Advances in Diagnosis amd Treatment. Curr. Probl. Dermatol. Elsner P., Eichmann A. (eds.), Basel, Karger, Vol. 24, pp. 110-122.Petersen E.E., Clad A. (1995). Genitale Chlamydieninfektionen. Deutsches Ärzteblatt 92, Heft 5, A-277-282.Weström L. (1996). Consequences of genital Chlamydia infections in women. In: Chlamydia Research. Angelika Stary (ed.). Proceedings of the third meeting of the European Society for Chlamydia Research, Vienna, Austria, 11.-14. Sept. pp. 137-140.Weström L.V. (1996). Chlamydia and its effect on reproduction. J.Brit.Fertil.Soc. 1: 23-30.

GENWAY BIOTECH manufactures and sells quality antibody products covering genome wide proteins.

6777 Nancy Ridge Drive San Diego, CA 92121 USA | Tel: (858)458-0866 |